{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.69","upperLimit":"100","value":"89.47"}]}],"title":"Overall Survival at 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.32","upperLimit":"96.4","value":"73.68"}]}],"title":"Overall Survival at 12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as time in months from the date of first study treatment to the date of death or withdrawal from study, whichever comes first. The percentage of patients alive at 6 months, 12 months, and 24 months will be reported. All patients who receive at least one dose of nivolumab will be included in the secondary analyses of OS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab and ipilimumab combination will be administered intravenously until disease progression or intolerable toxicity.\n\nNivolumab: Given at 240mg over 30 minutes (-5 / +15 minutes) every 2 weeks starting with Cycle 1 Day 1 for the first 16 weeks (1 cycle = 12 weeks). Starting with Cycle 2 Day 29, nivolumab will be given at 480mg IV over 60 minutes (-10 / +15 minutes) every 4 weeks.\n\nIpilimumab: Given at 1mg/Kg every 6 weeks starting with Cycle 1 Day 1 over approximately 90 minutes (-5 / +15 minutes).\n\nOn days when both nivolumab and ipilimumab are administered, nivolumab should be given first, followed by ipilimumab about 30 minutes after completion of nivolumab.\n\nPatients will be assessed for response every 12 weeks (±7 days).","id":"OG000","title":"Nivolumab + Ipilimumab"}],"paramType":"NUMBER","populationDescription":"Patients with Adenoid Cystic Carcinoma only.","reportingStatus":"POSTED","timeFrame":"Up to 2 years from start of treatment","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}